Christina A Wilson, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Christina A Wilson’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence G14281 · Cancelled
Licence status: Cancelled · since 1967 · Virginia Commonwealth University, Medical College of Virginia.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$16,228
Pharmacies billed $16,228 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 22% of their Part D prescriptions (34 of 154) in 2024. A higher opioid share than 9 in 10 peers; the typical nurse practitioner clinician is at 0%.
124 generic and 30 brand-name prescriptions · $16,228 in drug cost · 18 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xarelto | 20 | $9,950 | $497 |
| Oxycodone | 28 | $113 | $4 |
| Clopidogrel | 15 | $107 | $7 |
| Atorvastatin | 13 | $42 | $3 |
Year by year
| 2024 | 154 | 62 | 22% (34) | 19% | $16,228 |
| 2023 | 122 | 55 | 24% (29) | 12% | $8,696 |
| 2022 | 98 | 40 | 21% (21) | 17% | $11,567 |
| 2021 | 193 | 67 | 14% (27) | 24% | $40,337 |
| 2020 | 149 | 53 | 11% (16) | 17% | $13,140 |
| 2019 | 113 | 63 | 23% (26) | 11% | $7,488 |
| 2018 | 93 | 57 | 16% (15) | None | $4,120 |
| 2017 | 148 | 62 | 24% (36) | None | $3,062 |
| 2016 | 160 | 62 | 20% (32) | 10% | $13,121 |
| 2015 | 134 | 64 | 25% (33) | 8% | $3,951 |
| 2014 | 102 | 63 | 40% (41) | None | $4,453 |
| 2013 | 90 | 45 | 31% (28) | 0% | $2,469 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Clopidogrel | 14 | $306 | $22 |
| Oxycodone | 22 | $167 | $8 |
2022: 2 drugs
| Clopidogrel | 11 | $119 | $11 |
| Oxycodone | 20 | $68 | $3 |
2021: 5 drugs
| Xarelto | 26 | $14,719 | $566 |
| Ertapenem | 11 | $3,793 | $345 |
| Oxycodone | 19 | $120 | $6 |
| Clopidogrel | 19 | $108 | $6 |
| Pantoprazole | 11 | $99 | $9 |
2020: 3 drugs
| Xarelto | 14 | $7,998 | $571 |
| Clopidogrel | 29 | $240 | $8 |
| Atorvastatin | 20 | $218 | $11 |
2019: 2 drugs
| Clopidogrel | 35 | $270 | $8 |
| Hydrocodone-Acetaminophen | 14 | $54 | $4 |
2018: 2 drugs
| Clopidogrel | 24 | $235 | $10 |
| Hydrocodone-Acetaminophen | 12 | $73 | $6 |
2017: 4 drugs
| Clopidogrel | 50 | $318 | $6 |
| Gabapentin | 13 | $128 | $10 |
| Oxycodone | 11 | $119 | $11 |
| Hydrocodone-Acetaminophen | 17 | $84 | $5 |
2016: 3 drugs
| Clopidogrel | 43 | $375 | $9 |
| Hydrocodone-Acetaminophen | 25 | $247 | $10 |
| Atorvastatin | 24 | $244 | $10 |
2015: 2 drugs
| Clopidogrel | 52 | $406 | $8 |
| Hydrocodone-Acetaminophen | 18 | $165 | $9 |
2014: 2 drugs
| Clopidogrel | 23 | $343 | $15 |
| Hydrocodone-Acetaminophen | 27 | $216 | $8 |
2013: 2 drugs
| Clopidogrel | 34 | $1,907 | $56 |
| Hydrocodone-Acetaminophen | 17 | $117 | $7 |
Money from drug and device companies
$679 in 2025
| 2025 | 5 | 6 | None | $679 |
| 2023 | 5 | 9 | None | $930 |
| 2021 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Tactile Systems Technology | Flexitouch Plus | $164 | 2 payments
|
| Galderma Laboratories L.P. | Nemluvio | $140 | 1 payment
|
| Neurelis | Valtoco | $134 | 1 payment
|
| Revance Therapeutics | Daxxify | $126 | 1 payment
|
| Argenx US | Vyvgart | $115 | 1 payment
|
See all 6 published payments
| Argenx US | Meals · 2025-11-11 | Vyvgart | $115 |
| Tactile Systems Technology | Education · 2025-05-20 | Flexitouch Plus | $20 |
| Tactile Systems Technology | Meals · 2025-05-20 | Flexitouch Plus | $144 |
| Galderma Laboratories L.P. | Meals · 2025-05-13 | Nemluvio | $140 |
| Revance Therapeutics | Meals · 2025-02-12 | Daxxify | $126 |
| Neurelis | Meals · 2025-01-15 | Valtoco | $134 |
See earlier years (2023, 2021)
2023: $930
| Silk Road Medical | Enroute Transcarotid Stent | $279 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $272 | 4 payments
|
| Averitas Pharma | Qutenza | $130 | 1 payment
|
| Iti | Caplyta | $126 | 1 payment
|
| Mayne Pharma Commercial | Nextstellis | $124 | 1 payment
|
2021: $125
| Lilly USA | Reyvow | $125 | 1 payment
|
Professional record
- NPI
- 1598908907
- Licence
- CA 14281California G14281: Cancelled
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2009-04-15
- NPI last updated
- 2023-08-10
- NPI record certified
- 2023-08-10
This is when the NPI record was last certified, not a medical board exam.